Atriva Gets Undisclosed Amount in Seed Round; Receives Second Tranche
Executive Summary
Antivirals developer Atriva Therapeutics GMBH raised an undisclosed amount in its seed financing round led by Stichting Participatie Atriva and High-Tech Gründerfonds, which were joined by Dutch and German private investors.
Deal Industry
- Biotechnology
- Pharmaceuticals
Deal Status
- Final
Deal Type
-
Financing
- Venture Financing
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice